Cargando…
Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status
Targeted molecular therapy is an effective anticancer strategy. Anti‐EGFR monoclonal antibodies such as cetuximab (CTX) have been approved for the treatment of various malignancies, including colorectal cancer (CRC) with wild‐type KRAS. However, their efficacy in patients with KRAS mutations has not...
Autores principales: | Kato, Junko, Futamura, Manabu, Kanematsu, Masako, Gaowa, Siqin, Mori, Ryutaro, Tanahashi, Toshiyuki, Matsuhashi, Nobuhisa, Yoshida, Kazuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5057332/ https://www.ncbi.nlm.nih.gov/pubmed/26437179 http://dx.doi.org/10.1002/ijc.29881 |
Ejemplares similares
-
Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer
por: Kanematsu, Masako, et al.
Publicado: (2015) -
Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer
por: Tajima, Jesse Yu, et al.
Publicado: (2018) -
A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
por: Eng, Cathy, et al.
Publicado: (2016) -
Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report
por: Tokumaru, Yoshihisa, et al.
Publicado: (2019) -
A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
por: Weekes, Colin, et al.
Publicado: (2019)